Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ACRX closed up 1.94 percent on Friday, June 15, 2018, on 1.58 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical ACRX trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 15||Upper Bollinger Band Walk||Strength||0.00%|
|Jun 15||Wide Bands||Range Expansion||0.00%|
|Jun 15||Above Upper BB||Strength||0.00%|
|Jun 15||Overbought Stochastic||Strength||0.00%|
|Jun 15||Up 3 Days in a Row||Strength||0.00%|
|Jun 15||Up 4 Days in a Row||Strength||0.00%|
|Jun 15||Upper Bollinger Band Touch||Strength||0.00%|
|Jun 14||Expansion Breakout||Bullish Swing Setup||1.94%|
|Jun 14||Wide Bands||Range Expansion||1.94%|
|Jun 14||Above Upper BB||Strength||1.94%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ACRX news...
|52 Week High||5.75|
|52 Week Low||1.55|
|200-Day Moving Average||2.5092|
|50-Day Moving Average||2.8579|
|20-Day Moving Average||3.4785|
|10-Day Moving Average||3.752|
|Average True Range||0.1926|
|Chandelier Exit (Long, 3 ATRs )||3.7222|
|Chandelier Exit (Short, 3 ATRs )||3.4278|
|Upper Bollinger Band||4.1923|
|Lower Bollinger Band||2.7647|
|Percent B (%b)||1.01|
|MACD Signal Line||0.3006|
|Market Cap||190.59 Million|
|Num Shares||45.4 Million|
|Price-to-Earnings (P/E) Ratio||-3.82|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||4.43|
|Resistance 3 (R3)||4.43||4.37||4.39|
|Resistance 2 (R2)||4.37||4.31||4.36||4.37|
|Resistance 1 (R1)||4.28||4.27||4.33||4.28||4.36|
|Support 1 (S1)||4.13||4.16||4.18||4.13||4.04|
|Support 2 (S2)||4.07||4.12||4.06||4.03|
|Support 3 (S3)||3.98||4.07||4.01|
|Support 4 (S4)||3.98|